VYOME HOLDINGS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
VYOME HOLDINGS, INC. (HIND) reported Cash and Cash Equivalents, Period Increase (Decrease) of $79.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-22.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-02-22
- VYOME HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$365.00K, a 104.04% decline year-over-year.
- VYOME HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$2.66M, a 142.52% decline year-over-year.
- VYOME HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$9.27M.
- VYOME HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $12.37M.
- VYOME HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $79.00K.
- VYOME HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$51.87M, a 174.50% decline from fiscal 2016.
- VYOME HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $69.62M.
- VYOME HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$3.55M, a 181.05% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$3.02M derived: sum of 2 quarters · filed 2019-02-22 | -$12.29M derived: sum of 3 quarters · filed 2019-02-22 | $79.00K 10-K · filed 2019-02-22 |
| 2018-09-30 | -$2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | -$11.93M derived: sum of 2 quarters · filed 2018-11-02 | $444.00K 10-Q · filed 2018-11-02 | $9.47M derived: sum of 4 quarters · filed 2019-02-22 |
| 2018-06-30 | -$9.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $3.10M 10-Q · filed 2018-08-02 | $12.13M derived: sum of 3 quarters · filed 2019-02-22 | $18.39M derived: sum of 4 quarters · filed 2019-02-22 |
| 2018-03-31 | $12.37M 10-Q · filed 2018-05-10 | $21.39M derived: sum of 2 quarters · filed 2019-02-22 | $27.65M derived: sum of 3 quarters · filed 2019-02-22 | -$8.23M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-12-31 | $9.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $15.28M derived: sum of 2 quarters · filed 2019-02-22 | -$20.60M derived: sum of 3 quarters · filed 2019-02-22 | -$51.87M 10-K · filed 2019-02-22 |
| 2017-09-30 | $6.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | -$29.63M derived: sum of 2 quarters · filed 2018-11-02 | -$60.89M 10-Q · filed 2018-11-02 | $9.76M derived: sum of 4 quarters · filed 2018-11-02 |
| 2017-06-30 | -$35.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$67.15M 10-Q · filed 2018-08-02 | $3.50M derived: sum of 3 quarters · filed 2018-08-02 | $1.50M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | -$31.26M 10-Q · filed 2018-05-10 | $39.39M derived: sum of 2 quarters · filed 2018-05-10 | $37.38M derived: sum of 3 quarters · filed 2018-05-10 | $39.59M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $70.65M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $68.65M derived: sum of 2 quarters · filed 2018-03-05 | $70.85M derived: sum of 3 quarters · filed 2018-03-05 | $69.62M 10-K · filed 2018-03-05 |
| 2016-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $201.00K derived: sum of 2 quarters · filed 2017-11-03 | -$1.03M 10-Q · filed 2017-11-03 | $654.00K derived: sum of 4 quarters · filed 2018-03-05 |
| 2016-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $973.00K 10-Q · filed 2017-08-02 | $2.66M derived: sum of 3 quarters · filed 2018-03-05 | |
| 2016-03-31 | -$1.23M 10-Q · filed 2017-05-10 | $453.00K derived: sum of 2 quarters · filed 2018-03-05 | ||
| 2015-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | -$3.55M 10-K · filed 2018-03-05 | ||
| 2015-09-30 | -$5.23M 10-Q · filed 2016-11-10 | |||
| 2014-12-31 | $4.38M 10-K · filed 2017-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |